Xenomics, Inc. (XNOM.PK), a developer of non-invasive, next-generation molecular diagnostics, announces that Dr. Samuil Umansky, Chief Scientific Officer, is scheduled to give a talk today at the "microRNA in Human Disease and Development" conference in Boston, MA. Dr. Umansky will present a new platform technology developed by the company for detection of in vivo cell death by quantitative analysis of miRNA from urine and other bodily fluids.

The excessive apoptotic, or more rarely necrotic, cell death causes or accompanies numerous acute and chronic diseases and conditions, including brain stroke, acute myocardial infarction, Alzheimer's disease and other forms of dementia, as well as body reaction to various toxic causes and infections. Thus, a molecular technique enabling detection of in vivo cell death could be applied to many diagnostic areas and be used as companion diagnostics for the acceleration of drug development in clinical trials.

Xenomics recently developed a new technique that allows isolation of very short nucleic acids and oligonucleotides from urine and other bodily fluids. Using this method, the Xenomics team has demonstrated that urine contains various miRNA, including those specific for or overexpressed in placenta, liver, brain, and other tissues located outside of urinary system. This finding opens the possibility for non-invasive detection of cell death occurring in various tissues and organs.

Quantitative analysis of brain-specific miRNA isolated from urine and serum of patients with brain stroke or Alzheimer's disease demonstrated that the amount of neuron-specific miRNA was significantly higher both in urine and serum of those patients compared with matched controls, based on the analysis of samples from 100 human subjects completed to date. This data presents the first indication that the excessive cell death can be reliably detected in patients with acute and chronic diseases. The finding may lead to the development of non-invasive diagnostic tests based on analysis of cell-free miRNA from urine or serum. Such tests would be of particular importance for Alzheimer's disease, a devastating illness for which no molecular diagnostic or monitoring test exists. Over five million people in the United States are living with Alzheimer's disease; costs of Alzheimer's and other dementias to Medicare, Medicaid and businesses amount to more than $148 billion each year.

The possibility of detecting in vivo cell death by analysis of tissue-specific miRNA in bodily fluids complements Xenomics' original Transrenal DNA technology, which is based on analysis of "non-self" DNA sequences, including fetal DNA in the urine of pregnant women, DNA of various pathogens, and tumor-specific mutant DNA sequences.

About Xenomics

Xenomics is a molecular diagnostics company developing tests based on Transrenal nucleic acids (Tr-DNA and Tr-RNA including miRNA) and safe, simple urine collection techniques. The Company believes its proprietary technology has a broad range of detection / monitoring / screening applications, including prenatal conditions, infectious diseases, tissue transplantation, neurodegenerative disorders, various tumors, and can open significant new markets in the molecular diagnostics field. Currently, Xenomics is focusing on implementation of its urinary DNA-based test for high-risk Human Papilloma Virus (HPV) and development of other tests based on Tr-DNA and Tr-miRNA. Xenomics has a strong and broad IP portfolio of issued and pending patents covering different applications of the technology for molecular diagnostics.

Forward-Looking Statements

Statements about the Company's expectations, future commercial and development activities, applications of its technology, markets, and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product development, government regulation, market acceptance, dependence on key personnel, obtaining financing and other factors discussed in the Company's periodic reports filed with the Securities and Exchange Commission.


Tag Cloud